Lassa virus (LASV) is the etiologic agent of Lassa fever, a viral hemorrhagic fever (VHF) with a high case fatality rate of around 20-70% and is associated primarily in West African countries. Though ~80% of human infections are mild or asymptomatic, perhaps 20% lead to Lassa fever with 40% of those having a very severe clinical course with orifice and mucosal hemorrhage, circulatory shock, and multi-organ failure. LASV is an enveloped virus with a genome consisting of two ambisense, single-stranded RNA segments (Large (L) and Small (S)) that each code for two proteins, with all four proteins being multifunctional. The ambisense RNAs give rise to early translation of the nucleoprotein (NP) and large (L) protein (RNA-dependent RNA polymerase) components followed by later translation of the glycoprotein complex (GPC) proteins (GP1 and GP2) as well as the zinc-binding protein (Z, matrix protein). LASV is attracting more global attention due to the continuing geographical spread of its rodent reservoirs, increasing outbreak frequency, its importation to other continents, significant potential for weaponization, and the genesis of new lineages in West Africa.
GeneTex has launched these following antibodies:
Lassa virus Nucleoprotein antibody [HL1392] (GTX636832)
Lassa virus Nucleoprotein antibody [HL1390] (GTX636830)
We being the Antibodies supplier in India welcomes your enquiry for this and other primary and secondary antibody.